Kathryn J Ruddy1, Daniel J Schaid2, Ann H Partridge3, Nicholas B Larson2, Anthony Batzler2, Lothar Häberle4, Ralf Dittrich4, Peter Widschwendter5, Visnja Fink5, Emanuel Bauer5, Judith Schwitulla4, Matthias Rübner4, Arif B Ekici6, Viktoria Aivazova-Fuchs7, Elizabeth A Stewart8, Matthias W Beckmann4, Elizabeth Ginsburg9, Liewei Wang10, Richard M Weinshilboum10, Fergus J Couch11, Wolfgang Janni5, Brigitte Rack5, Celine Vachon12, Peter A Fasching4. 1. Department of Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: ruddy.kathryn@mayo.edu. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 3. Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. 5. Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany. 6. Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. 7. Department of Gynecology, Klinik Bad Trissl, Oberaudorf, Germany. 8. Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota. 9. Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts. 10. Department of Pharmacology, Mayo Clinic, Rochester, Minnesota. 11. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 12. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVE: To study how genetics may play a role in determining risk of chemotherapy-related amenorrhea (CRA) in young women with breast cancer. DESIGN: Genome-wide association study. SETTING: Not applicable. PATIENT(S): Premenopausal women ≤45 years of age enrolled in one of these three trials were included if they had at least one menstrual case report form after chemotherapy ended and if they were of European ancestry. Forms during and up to 3 months after receipt of GnRH agonist were excluded. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The association of single-nucleotide polymorphisms with post-chemotherapy menstruation adjusted for trial and arm, age, tamoxifen use, and nodal status. RESULT(S): The median age of the 1,168 women was 41 years (range 19-45). Among these, 457 (39%) never resumed menses after chemotherapy. Older age, tamoxifen use, and node-negative disease were associated with increased risk of CRA. Adjusting for these, rs147451859, in an intron of PPCDC (phosphopantothenoylcysteine decarboxylase), and rs17587029, located 5' upstream of RPS20P11 (ribosomal protein S20 pseudogene 11), were associated with post-chemotherapy menstruation. CONCLUSION(S): Genetic variation may contribute to risk of CRA. Better prediction of who will experience CRA may inform reproductive and treatment decision making in young women with cancer.
OBJECTIVE: To study how genetics may play a role in determining risk of chemotherapy-related amenorrhea (CRA) in young women with breast cancer. DESIGN: Genome-wide association study. SETTING: Not applicable. PATIENT(S): Premenopausal women ≤45 years of age enrolled in one of these three trials were included if they had at least one menstrual case report form after chemotherapy ended and if they were of European ancestry. Forms during and up to 3 months after receipt of GnRH agonist were excluded. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The association of single-nucleotide polymorphisms with post-chemotherapy menstruation adjusted for trial and arm, age, tamoxifen use, and nodal status. RESULT(S): The median age of the 1,168 women was 41 years (range 19-45). Among these, 457 (39%) never resumed menses after chemotherapy. Older age, tamoxifen use, and node-negative disease were associated with increased risk of CRA. Adjusting for these, rs147451859, in an intron of PPCDC (phosphopantothenoylcysteine decarboxylase), and rs17587029, located 5' upstream of RPS20P11 (ribosomal protein S20 pseudogene 11), were associated with post-chemotherapy menstruation. CONCLUSION(S): Genetic variation may contribute to risk of CRA. Better prediction of who will experience CRA may inform reproductive and treatment decision making in young women with cancer.
Authors: Joanne M Murabito; Qiong Yang; Caroline Fox; Peter W F Wilson; L Adrienne Cupples Journal: J Clin Endocrinol Metab Date: 2005-03-15 Impact factor: 5.958
Authors: Oliver H Tam; Alexei A Aravin; Paula Stein; Angelique Girard; Elizabeth P Murchison; Sihem Cheloufi; Emily Hodges; Martin Anger; Ravi Sachidanandam; Richard M Schultz; Gregory J Hannon Journal: Nature Date: 2008-04-10 Impact factor: 49.962
Authors: Matthew Daugherty; Boris Polanuyer; Michael Farrell; Michael Scholle; Athanasios Lykidis; Valerie de Crécy-Lagard; Andrei Osterman Journal: J Biol Chem Date: 2002-03-28 Impact factor: 5.157
Authors: Sandra M Swain; Stephanie R Land; Marcie W Ritter; Joseph P Costantino; Reena S Cecchini; Eleftherios P Mamounas; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2008-02-27 Impact factor: 4.872
Authors: Deepika Garg; Huong Dieu Meeks; Erica Johnstone; Sarah L Berga; Ken R Smith; Jim Hotaling; Joseph M Letourneau Journal: F S Rep Date: 2021-08-30
Authors: Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Elmar Stickeler; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Tanja N Fehm; Erik Belleville; Simon Bader; Katharina Seitz; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P Lux; Bahriye Aktas; Maggie Banys-Paluchowski; Andreas Schneeweiss; Nadia Harbeck; Rachel Würstlein; Andreas D Hartkopf; Achim Wöckel; Barbara Seliger; Chiara Massa; Hans-Christian Kolberg Journal: Geburtshilfe Frauenheilkd Date: 2022-06-03 Impact factor: 2.754
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24